BR112024002198A2 - Composições farmacêuticas compreendendo proteínas de fusão do hla - Google Patents

Composições farmacêuticas compreendendo proteínas de fusão do hla

Info

Publication number
BR112024002198A2
BR112024002198A2 BR112024002198A BR112024002198A BR112024002198A2 BR 112024002198 A2 BR112024002198 A2 BR 112024002198A2 BR 112024002198 A BR112024002198 A BR 112024002198A BR 112024002198 A BR112024002198 A BR 112024002198A BR 112024002198 A2 BR112024002198 A2 BR 112024002198A2
Authority
BR
Brazil
Prior art keywords
fusion proteins
pharmaceutical compositions
hla fusion
hla
treating
Prior art date
Application number
BR112024002198A
Other languages
English (en)
Inventor
Anahita Rafiei
Anil Kumar
Christoph Renner
Marroquin Belaunzaran Osiris
Original Assignee
Immunos Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21190004.8A external-priority patent/EP4129323A1/en
Priority claimed from EP21190005.5A external-priority patent/EP4130029A1/en
Application filed by Immunos Therapeutics Ag filed Critical Immunos Therapeutics Ag
Publication of BR112024002198A2 publication Critical patent/BR112024002198A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hematology (AREA)

Abstract

composições farmacêuticas compreendendo proteínas de fusão do hla. a invenção se refere a composições farmacêuticas compreendendo proteínas de fusão do hla para uso em tratamento de doença neoplásica. a invenção também provê medicamentos de combinação compreendendo tanto proteínas de fusão do hla quanto inibidores do ponto de controle, para uso em tratamento de câncer.
BR112024002198A 2021-08-05 2022-08-05 Composições farmacêuticas compreendendo proteínas de fusão do hla BR112024002198A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21190004.8A EP4129323A1 (en) 2021-08-05 2021-08-05 A modified hla-b57 with increased expression levels
EP21190005.5A EP4130029A1 (en) 2021-08-05 2021-08-05 Pharmaceutical compositions comprising hla fusion proteins
EP21207324 2021-11-09
PCT/EP2022/072130 WO2023012347A1 (en) 2021-08-05 2022-08-05 Pharmaceutical compositions comprising hla fusion proteins

Publications (1)

Publication Number Publication Date
BR112024002198A2 true BR112024002198A2 (pt) 2024-04-30

Family

ID=83115511

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112024002198A BR112024002198A2 (pt) 2021-08-05 2022-08-05 Composições farmacêuticas compreendendo proteínas de fusão do hla
BR112024002196A BR112024002196A2 (pt) 2021-08-05 2022-08-05 Hla-b57 modificado com níveis de expressão aumentados

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112024002196A BR112024002196A2 (pt) 2021-08-05 2022-08-05 Hla-b57 modificado com níveis de expressão aumentados

Country Status (7)

Country Link
EP (2) EP4380968A1 (pt)
KR (2) KR20240042017A (pt)
AU (2) AU2022323540A1 (pt)
BR (2) BR112024002198A2 (pt)
CA (2) CA3227284A1 (pt)
IL (2) IL310612A (pt)
WO (2) WO2023012348A1 (pt)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
EP2643349B1 (en) 2010-11-26 2019-09-04 Molecular Partners AG Designed repeat proteins binding to serum albumin
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
AU2016214439B2 (en) 2015-02-04 2019-05-02 Universität Basel Use of HLA-B27 homodimers for cancer treatment
CN108779164B (zh) 2016-03-08 2023-06-09 苏黎世大学 Hla-b57开放型构象异构体
CN109562171B (zh) 2016-08-10 2023-10-17 苏黎世大学 MHC Ia类开放型构象异构体
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段

Also Published As

Publication number Publication date
AU2022324711A1 (en) 2024-02-01
BR112024002196A2 (pt) 2024-04-30
KR20240042017A (ko) 2024-04-01
IL310612A (en) 2024-04-01
CA3227299A1 (en) 2023-02-09
WO2023012348A1 (en) 2023-02-09
EP4380968A1 (en) 2024-06-12
IL310615A (en) 2024-04-01
AU2022323540A1 (en) 2024-02-15
WO2023012347A1 (en) 2023-02-09
EP4380595A1 (en) 2024-06-12
CA3227284A1 (en) 2023-02-09
KR20240045259A (ko) 2024-04-05

Similar Documents

Publication Publication Date Title
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
BR112018002585A2 (pt) 5-bromo-2,6-di-(1h-pirazol-1-il)pirimidin-4-amina para uso no tratamento de câncer
BR112017013661A8 (pt) Conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica
UY38700A (es) Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
CL2011001536A1 (es) Compuestos derivados de pirimidin-2-il-1h-indol, inhibidores de la proteina quinasa atr; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del cancer.
PE20150646A1 (es) Metodos de tratamiento de una tauopatia
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
CR20110608A (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
UY32203A (es) Amino pirimidinas y su uso en terapia
ECSP088733A (es) Anticuerpos anti-5t4 y usos de los mismos
CL2016002667A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
BR112017025781A2 (pt) derivados de 2-(pirazolopiridin-3-il)pirimidina como inibidores de jak
UY30304A1 (es) Moduladores de mglur5 i
BR112019008417A2 (pt) compostos de peptídeo tirosina-tirosina cíclico acoplados a anticorpo como moduladores de receptores de neuropeptídeo y
PA8799901A1 (es) Derivado de triazol 1,3,5-trisustituido
CL2008000910A1 (es) Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide.
UY30308A1 (es) Moduladores de mglur5 v
CL2008001323A1 (es) Compuestos derivados de triazolil aminopiridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
BR112022023622A2 (pt) Proteína de ligação a cd40
CO2021008665A2 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
BR112015016817A8 (pt) métodos para derivar um sacarídeo, para conjugar um derivado de sacarídeo e para incitar uma resposta imune em um mamífero, derivado de sacarídeo, conjugado de um derivado de sacarídeo, composição farmacêutica, e, uso de um conjugado ou composição farmacêutica
BR112021022514A2 (pt) Conjugados de anticorpo e fármaco
BR112022008756A2 (pt) Conjugados anticorpo-fármaco anti-mesotelina eribulina e métodos de uso
UY30309A1 (es) Moduladores de mglur5 ii